Trial Profile

A Randomized, Blinded, Peer-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 18-59 Years

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal-polysaccharide-vaccine-groups-ACYW135-Bio-Med
Indications Meningococcal meningitis
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Tianjin CanSino Biotechnology

21 Mar 2025 Planned End Date changed from 1 Oct 2024 to 1 Jun 2025.
15 Aug 2024 Status changed from not yet recruiting to active, no longer recruiting.
31 Jan 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com